Filing of four new patent applications

Filing of four new patent applications on novel target innovation and new siRNA chemistries

London, UK, 07 February 2023- e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces the filing of four new patent applications to protect innovation around novel gene targets, associated disease relevant biology as well as proprietary siRNA (‘short interfering RNA’) stabilisation chemistries.

The four new patent applications add to a rapidly growing patent portfolio reflecting the Company’s continued intense rate of innovation associated with developing a computationally driven in-house pipeline of RNAi drug candidates across a range of therapeutic areas. The new patent applications build on an active period of IP generation reported in 2022 where a series of patent applications were filed to protect 13 inventions. 

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: 

“This latest announcement of patent filings reflects our continued pace of innovation and progress towards an in-house pipeline of first-in-class RNAi candidates derived from our computational platform. We will continue to build on this progress, maintain the momentum of invention and actively protect our expanding intellectual property portfolio.”